>>Signaling Pathways>> GPCR/G protein>> OX Receptor>>Orexin receptor antagonist 5

Orexin receptor antagonist 5

Catalog No.GC65382

Products are for research use only. Not for human use. We do not sell to patients.

Orexin receptor antagonist 5 Chemical Structure

Cas No.: 1352834-55-9

Size 가격 재고 수량
5mg
US$432.00
재고 있음
10mg
US$720.00
재고 있음
25mg
US$1,395.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

Description of Orexin receptor antagonist 5

Orexin receptor antagonist 5 (compound 1) is a potent orexin receptor antagonist. rexin receptor antagonist 5 can be used for the research of primary insomnia[1].

[1]. Turku A, et al. Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands. J Med Chem. 2016 Sep 22;59(18):8263-75.

Chemical Properties of Orexin receptor antagonist 5

Cas No. 1352834-55-9 SDF
Formula C23H23ClN6O2 M.Wt 450.92
Solubility Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of Orexin receptor antagonist 5

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.2177 mL 11.0884 mL 22.1769 mL
5 mM 443.5 μL 2.2177 mL 4.4354 mL
10 mM 221.8 μL 1.1088 mL 2.2177 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of Orexin receptor antagonist 5

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

리뷰

Review for Orexin receptor antagonist 5

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Orexin receptor antagonist 5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.